Data gathered: October 26
Alternative Data for Karyopharm Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 31 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,791 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,564 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
| Linkedin Employees | 323 | Sign up | Sign up | Sign up |
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
| Price | $6.34 |
| Target Price | Sign up |
| Volume | 84,550 |
| Market Cap | $101M |
| Year Range | $3.54 - $9.83 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
How Recent Developments Are Shaping the Karyopharm Therapeutics Investment StoryOctober 13 - Yahoo |
 |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $34.00 Consensus Target Price from BrokeragesSeptember 17 - ETF Daily News |
|
Adage Capital Partners GP L.L.C. Lowers Stake in Karyopharm Therapeutics Inc. $KPTISeptember 9 - ETF Daily News |
|
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $34.00 Average PT from BrokeragesAugust 23 - ETF Daily News |
 |
Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsightOctober 23 - PR Newswire UK |
 |
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026October 8 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 38M | 1.1M | 37M | -37M | -24M | -4.065 |
| Q1 '25 | 30M | 1.3M | 29M | -23M | -12M | -2.770 |
| Q4 '24 | 31M | 1.3M | 29M | -31M | -20M | -0.240 |
| Q3 '24 | 39M | 1.3M | 37M | -32M | -21M | -0.257 |
| Q2 '24 | 43M | 1.6M | 41M | 24M | 33M | 0.150 |
Insider Transactions View All
| Abate Kristin filed to sell 10,046 shares at $6.3. October 3 '25 |
| Abate Kristin filed to sell 10,408 shares at $6.4. September 16 '25 |
| Cheng Sohanya Roshan filed to sell 35,856 shares at $6.4. September 16 '25 |
| Rangwala Reshma filed to sell 29,390 shares at $6.4. September 16 '25 |
| Poulton Stuart filed to sell 27,710 shares at $6.4. September 16 '25 |
Similar companies
Read more about Karyopharm Therapeutics (KPTI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Karyopharm Therapeutics?
The Market Cap of Karyopharm Therapeutics is $101M.
What is the current stock price of Karyopharm Therapeutics?
Currently, the price of one share of Karyopharm Therapeutics stock is $6.34.
How can I analyze the KPTI stock price chart for investment decisions?
The KPTI stock price chart above provides a comprehensive visual representation of Karyopharm Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Karyopharm Therapeutics shares. Our platform offers an up-to-date KPTI stock price chart, along with technical data analysis and alternative data insights.
Does KPTI offer dividends to its shareholders?
As of our latest update, Karyopharm Therapeutics (KPTI) does not offer dividends to its shareholders. Investors interested in Karyopharm Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Karyopharm Therapeutics?
Some of the similar stocks of Karyopharm Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
